Editas Medicine Statistics
Total Valuation
Editas Medicine has a market cap or net worth of $246.12 million. The enterprise value is $46.24 million.
Important Dates
The next estimated earnings date is Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Editas Medicine has 83.71 million shares outstanding. The number of shares has increased by 4.29% in one year.
| Current Share Class | 83.71M |
| Shares Outstanding | 83.71M |
| Shares Change (YoY) | +4.29% |
| Shares Change (QoQ) | +0.53% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 53.50% |
| Float | 83.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.05 |
| Forward PS | 17.49 |
| PB Ratio | 4.10 |
| P/TBV Ratio | 3.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.08, with a Debt / Equity ratio of 0.50.
| Current Ratio | 3.08 |
| Quick Ratio | 3.03 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -93.52 |
Financial Efficiency
Return on equity (ROE) is -140.82% and return on invested capital (ROIC) is -61.37%.
| Return on Equity (ROE) | -140.82% |
| Return on Assets (ROA) | -36.80% |
| Return on Invested Capital (ROIC) | -61.37% |
| Return on Capital Employed (ROCE) | -108.77% |
| Revenue Per Employee | $145,679 |
| Profits Per Employee | -$1.02M |
| Employee Count | 246 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.32% in the last 52 weeks. The beta is 2.16, so Editas Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.16 |
| 52-Week Price Change | -42.32% |
| 50-Day Moving Average | 1.95 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 69.02 |
| Average Volume (20 Days) | 3,451,083 |
Short Selling Information
The latest short interest is 8.43 million, so 10.07% of the outstanding shares have been sold short.
| Short Interest | 8.43M |
| Short Previous Month | 9.00M |
| Short % of Shares Out | 10.07% |
| Short % of Float | 10.11% |
| Short Ratio (days to cover) | 4.26 |
Income Statement
In the last 12 months, Editas Medicine had revenue of $35.84 million and -$251.23 million in losses. Loss per share was -$3.04.
| Revenue | 35.84M |
| Gross Profit | -161.41M |
| Operating Income | -207.24M |
| Pretax Income | -193.45M |
| Net Income | -251.23M |
| EBITDA | -200.92M |
| EBIT | -207.24M |
| Loss Per Share | -$3.04 |
Full Income StatementBalance Sheet
The company has $220.96 million in cash and $31.13 million in debt, giving a net cash position of $189.83 million or $2.27 per share.
| Cash & Cash Equivalents | 220.96M |
| Total Debt | 31.13M |
| Net Cash | 189.83M |
| Net Cash Per Share | $2.27 |
| Equity (Book Value) | 62.42M |
| Book Value Per Share | 0.75 |
| Working Capital | 151.73M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$208.21 million and capital expenditures -$7.07 million, giving a free cash flow of -$215.28 million.
| Operating Cash Flow | -208.21M |
| Capital Expenditures | -7.07M |
| Free Cash Flow | -215.28M |
| FCF Per Share | -$2.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -578.28% |
| Pretax Margin | -701.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Editas Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.29% |
| Shareholder Yield | -4.29% |
| Earnings Yield | -106.42% |
| FCF Yield | -91.19% |
Analyst Forecast
The average price target for Editas Medicine is $6.20, which is 110.88% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.20 |
| Price Target Difference | 110.88% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | -12.72% |
| EPS Growth Forecast (5Y) | -17.95% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Editas Medicine has an Altman Z-Score of -9.1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.1 |
| Piotroski F-Score | 1 |
